XERS
Xeris Biopharma Holdings, Inc.
NASDAQ · USHealthcareBiotechnology
$8.60-2.27%
Price as of Jul 20, 2026
XERS profitability
Xeris Biopharma Holdings, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 81.6%
- EBITDA margin
- 14.7%
- EBIT margin
- 11.4%
- Net margin
- 3.8%
- Free cash flow margin
- 15.0%
Returns
- Return on equity
- 92.3%
- Return on assets
- 3.1%
- Return on invested capital
- 71.3%
- Asset turnover
- 0.81x
Cash efficiency
- Cash from operations
- $48.5M
- Cash per share
- $0.65
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.